Background Hepatitis C virus (HCV) treatment drugs--such as Harvoni, Sovaldi, Viekira Pak, and Technivie--are classified as Direct Acting Antiviral Agents (DAAs). The relationship between DAA treatment and liver cancer, or hepatocellular carcinoma (HCC), is a complex one that has been the subject of several studies in the past year. While … [Read more...]
August Update: Possible Link Between Hepatitis C Drugs & Liver Cancer
In the past several years, there has been much controversy surrounding the possible link between a class of Hepatitis C drugs known as direct-acting antivirals (DAAs) and hepatocellular carcinoma (HCC), or liver cancer. The DAA drugs include Harvoni, Sovaldi, Viekira Pak, Technivie, Olysio, Daklinza, Epclusa, and Zepatier. In July, I wrote an … [Read more...]
July 2017 Update: Any Link Between Hepatitis C Drugs and Liver Cancer?
A recent study from the July 2017 edition of Gastroenterology sought to investigate the relationship between Direct Acting Antiviral Agents (DAA) -- such as Harvoni, Sovaldi, Viekira Pak, and Technivie -- and liver cancer, or hepatocellular carcinoma (HCC). Previously, the medical literature on this subject was relatively sparse, as well as … [Read more...]